Clinical Trial Update: Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD [Phase 2]

View source ↗

Summary

Phase II study assessing cardiac safety of two doses of CHF5993 combined with CHF1535 BID vs CHF1535 BID in moderate to severe COPD; completed

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• CHF1535
• CHF5993

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Status: COMPLETED